Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length

Journal of Neurochemistry

Volumn 78, Issue 4, 2001, Pages 694-703

  Hansson, Oskar ^a   Castilho, Roger F ^b   Korhonen, Laura ^c   Lindholm, Dan ^c   Bates, Gillian P ^d   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UPPSALA UNIVERSITY   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cell death; Excitotoxicity; Huntington's disease; Malonate; N methyl D aspartate; Transgenic mouse

Indexed keywords

CASPASE INHIBITOR; DIZOCILPINE; EXCITOTOXIN; GLUTAMIC ACID; MALONIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; PROTEIN BCL X; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CELL DEATH; CELL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; ONSET AGE; PRIORITY JOURNAL; STRESS; STRIATE CORTEX; TRANSGENIC MOUSE;

AGING; AMINO ACID CHLOROMETHYL KETONES; ANIMALS; BCL-X PROTEIN; BLOOD GLUCOSE; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MALONATES; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUCCINATE DEHYDROGENASE; SYNAPTOSOMES; TRINUCLEOTIDE REPEATS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0034889544     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00482.x     Document Type: Article

References (54)

1. Alternative excitotoxic hypotheses
2. An investigation of the mechanisms of delayed neurodegeneration caused by direct injection of quinolinate into the rat striatum in vivo
3. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerativeillnesses?
4. Aging, energy, and oxidative stress in neurodegenerative diseases
5. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
6. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate
7. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
8. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease
9. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
10. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormalchoreiform movements in primates
11. Oxidative damage and metabolic dysfunction in Huntington's disease. Selective vulnerability of the basal ganglia
12. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
13. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
14. Ischemic tolerance in the brain
15. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
16. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
17. Trinucleotide repeat length instability and age of onset in Huntington's disease
18. Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation
19. Dopaminergic modulation of excitotoxicity in rat striatum. Evidence from nigrostriatal lesions
20. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate
21. Inhibition of succinate by malonic acid produces an 'excitotoxic' lesion in rat striatum
22. Mitochondrial defect in Huntington's disease caudate nucleus
23. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-inducedstriatal excitotoxicity
24. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons
25. Malonate produces striatal lesions by indirect NMDA receptor activation
26. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitroproprionic acid-induced striatal toxicity
27. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes
28. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease
29. Mechanisms of ischemic preconditioning
30. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy
31. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice
32. Regulation of X chromosome-linked inhibitor of apoptosis in mammalian cells by NAIP and a related family of IAP genes
33. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
34. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation
35. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
36. Huntington's disease. Translating a CAG repeat into a pathogenic mechanism
37. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
38. N-methyl-D-aspartate receptormediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis
39. Calciumdependent and-independent release of glutamate from synaptosomes monitored by continuous fluorometry
40. Altered strital amino acid neurotransmitter release monitored using microdialys in R6/1 Huntington transgenic mice
41. Recent advances in understanding the pathogenesis of Huntington's disease
42. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease
43. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation
44. Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration
45. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia
46. Determination of the activity of succinate, NADH, choline, and alpha-glycerophosphate dehydrogenases
47. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
48. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
49. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form: Nat
50. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
51. Huntington disease
52. Involvement of dopaminergic receptors in quinolinate-induced striatal lesions
53. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator